Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1999 Nov;67(5):585–590. doi: 10.1136/jnnp.67.5.585

Lack of restriction of T cell receptor β variable gene usage in cerebrospinal fluid lymphocytes in acute optic neuritis

R Heard 1, S Teutsch 1, B Bennetts 1, S Lee 1, E Deane 1, G Stewart 1
PMCID: PMC1736607  PMID: 10519862

Abstract

OBJECTIVES—There have been many studies reporting restricted patterns of T cell receptor usage in established multiple sclerosis and these have led to clinical trials of immunomodulation directed at deleting clonal T cell populations. The present study aims to test the hypothesis that highly restricted T cell populations are also present in the CSF in the earliest clinical stages of acute demyelinating disease of the CNS.
METHODS—T cell receptor Vβ (TCRBV) gene expression was studied in CSF and blood in nine patients with acute optic neuritis within 7 days of onset of symptoms, six patients with an acute relapse of multiple sclerosis, and 13 control subjects. RNA was extracted and cDNA synthesised from unstimulated CSF and blood lymphocytes, and TCRBV gene segments were amplified from the cDNA by polymerase chain reaction (PCR) using 21 family specific primers. PCR products were separated by polyacrylamide gel electrophoresis and detected via a labelled oligonucleotide probe. A semiquantitative analysis of band intensity was performed by laser densitometry.
RESULTS—TCRBV mRNA was detected in the CSF of eight of nine patients with optic neuritis, six of six patients with multiple sclerosis, and five of 13 controls, and was closely correlated with the presence of oligoclonal IgG. Usage of a single TCRBV family was demonstrated in two of nine patients with optic neuritis and two of six patients with multiple sclerosis. The number of TCRBV families expressed in the other patients ranged between 5 and 15 (optic neuritis) and 4 and 17 (multiple sclerosis).
CONCLUSIONS—There is a relative lack of restriction of TCRBV usage by CSF lymphocytes in the very earliest stages (<7 days) of acute optic neuritis. This may imply either that multiple sclerosis is not a monoclonal disease even at onset, or that the autoimmune response has widened before the disease becomes clinically evident. This may have important consequences for the design of immune therapies in multiple sclerosis. Further studies are required to determine whether the CSF T cell repertoire at presentation has prognostic importance. Longitudinal studies are required to follow the CSF T cell repertoire from the time of presentation and to determine whether it may have prognostic significance.



Full Text

The Full Text of this article is available as a PDF (97.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acha-Orbea H., Mitchell D. J., Timmermann L., Wraith D. C., Tausch G. S., Waldor M. K., Zamvil S. S., McDevitt H. O., Steinman L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 1988 Jul 15;54(2):263–273. doi: 10.1016/0092-8674(88)90558-2. [DOI] [PubMed] [Google Scholar]
  2. Beck R. W., Cleary P. A., Trobe J. D., Kaufman D. I., Kupersmith M. J., Paty D. W., Brown C. H. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993 Dec 9;329(24):1764–1769. doi: 10.1056/NEJM199312093292403. [DOI] [PubMed] [Google Scholar]
  3. Ben-Nun A., Liblau R. S., Cohen L., Lehmann D., Tournier-Lasserve E., Rosenzweig A., Zhang J. W., Raus J. C., Bach M. A. Restricted T-cell receptor V beta gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: predominant genes vary in individuals. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2466–2470. doi: 10.1073/pnas.88.6.2466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Birebent B., Semana G., Commeurec A., Edan G., Genetet B., Genetet N. TCR repertoire and cytokine profiles of cerebrospinal fluid- and peripheral blood-derived T lymphocytes from patients with multiple sclerosis. J Neurosci Res. 1998 Mar 15;51(6):759–770. doi: 10.1002/(SICI)1097-4547(19980315)51:6<759::AID-JNR9>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  5. Birnbaum G., van Ness B. Quantitation of T-cell receptor V beta chain expression on lymphocytes from blood, brain, and spinal fluid in patients with multiple sclerosis and other neurological diseases. Ann Neurol. 1992 Jul;32(1):24–30. doi: 10.1002/ana.410320106. [DOI] [PubMed] [Google Scholar]
  6. Bourdette D. N., Chou Y. K., Whitham R. H., Buckner J., Kwon H. J., Nepom G. T., Buenafe A., Cooper S. A., Allegretta M., Hashim G. A. Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes. J Immunol. 1998 Jul 15;161(2):1034–1044. [PubMed] [Google Scholar]
  7. Bourdette D. N., Whitham R. H., Chou Y. K., Morrison W. J., Atherton J., Kenny C., Liefeld D., Hashim G. A., Offner H., Vandenbark A. A. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol. 1994 Mar 1;152(5):2510–2519. [PubMed] [Google Scholar]
  8. Burns F. R., Li X. B., Shen N., Offner H., Chou Y. K., Vandenbark A. A., Heber-Katz E. Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar V alpha and V beta chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J Exp Med. 1989 Jan 1;169(1):27–39. doi: 10.1084/jem.169.1.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Choi Y. W., Kotzin B., Herron L., Callahan J., Marrack P., Kappler J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8941–8945. doi: 10.1073/pnas.86.22.8941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chou Y. K., Buenafe A. C., Dedrick R., Morrison W. J., Bourdette D. N., Whitham R., Atherton J., Lane J., Spoor E., Hashim G. A. T cell receptor V beta gene usage in the recognition of myelin basic protein by cerebrospinal fluid- and blood-derived T cells from patients with multiple sclerosis. J Neurosci Res. 1994 Feb 1;37(2):169–181. doi: 10.1002/jnr.490370203. [DOI] [PubMed] [Google Scholar]
  11. Chou Y. K., Morrison W. J., Weinberg A. D., Dedrick R., Whitham R., Bourdette D. N., Hashim G., Offner H., Vandenbark A. A. Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol. 1994 Mar 1;152(5):2520–2529. [PubMed] [Google Scholar]
  12. Correale J., McMillan M., McCarthy K., Le T., Weiner L. P. Isolation and characterization of autoreactive proteolipid protein-peptide specific T-cell clones from multiple sclerosis patients. Neurology. 1995 Jul;45(7):1370–1378. doi: 10.1212/wnl.45.7.1370. [DOI] [PubMed] [Google Scholar]
  13. Genevée C., Diu A., Nierat J., Caignard A., Dietrich P. Y., Ferradini L., Roman-Roman S., Triebel F., Hercend T. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol. 1992 May;22(5):1261–1269. doi: 10.1002/eji.1830220522. [DOI] [PubMed] [Google Scholar]
  14. Gold D. P., Smith R. A., Golding A. B., Morgan E. E., Dafashy T., Nelson J., Smith L., Diveley J., Laxer J. A., Richieri S. P. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide. J Neuroimmunol. 1997 Jun;76(1-2):29–38. doi: 10.1016/s0165-5728(97)00029-5. [DOI] [PubMed] [Google Scholar]
  15. Hafler D. A., Duby A. D., Lee S. J., Benjamin D., Seidman J. G., Weiner H. L. Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1988 Apr 1;167(4):1313–1322. doi: 10.1084/jem.167.4.1313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jason J., Inge K. L. The effects of mitogens, IL-2 and anti-CD3 antibody on the T-cell receptor V beta repertoire. Scand J Immunol. 1996 Jun;43(6):652–661. doi: 10.1046/j.1365-3083.1996.d01-271.x. [DOI] [PubMed] [Google Scholar]
  17. Kotzin B. L., Karuturi S., Chou Y. K., Lafferty J., Forrester J. M., Better M., Nedwin G. E., Offner H., Vandenbark A. A. Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9161–9165. doi: 10.1073/pnas.88.20.9161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lee K. H., Hashimoto S. A., Hooge J. P., Kastrukoff L. F., Oger J. J., Li D. K., Paty D. W. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1991 May;41(5):657–660. doi: 10.1212/wnl.41.5.657. [DOI] [PubMed] [Google Scholar]
  19. Lee S. J., Wucherpfennig K. W., Brod S. A., Benjamin D., Weiner H. L., Hafler D. A. Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Ann Neurol. 1991 Jan;29(1):33–40. doi: 10.1002/ana.410290109. [DOI] [PubMed] [Google Scholar]
  20. Lehmann P. V., Forsthuber T., Miller A., Sercarz E. E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 1992 Jul 9;358(6382):155–157. doi: 10.1038/358155a0. [DOI] [PubMed] [Google Scholar]
  21. Miller D. H., Ormerod I. E., McDonald W. I., MacManus D. G., Kendall B. E., Kingsley D. P., Moseley I. F. The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry. 1988 Dec;51(12):1569–1571. doi: 10.1136/jnnp.51.12.1569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Miller S. D., Vanderlugt C. L., Begolka W. S., Pao W., Yauch R. L., Neville K. L., Katz-Levy Y., Carrizosa A., Kim B. S. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med. 1997 Oct;3(10):1133–1136. doi: 10.1038/nm1097-1133. [DOI] [PubMed] [Google Scholar]
  23. Morrissey S. P., Miller D. H., Kendall B. E., Kingsley D. P., Kelly M. A., Francis D. A., MacManus D. G., McDonald W. I. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain. 1993 Feb;116(Pt 1):135–146. doi: 10.1093/brain/116.1.135. [DOI] [PubMed] [Google Scholar]
  24. Muraro P. A., Vergelli M., Kalbus M., Banks D. E., Nagle J. W., Tranquill L. R., Nepom G. T., Biddison W. E., McFarland H. F., Martin R. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. J Clin Invest. 1997 Jul 15;100(2):339–349. doi: 10.1172/JCI119539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Navarrete C., Bottazzo G. F. In search of TCR restriction in autoreactive T cell in human autoimmunity: why is it so elusive? Clin Exp Immunol. 1993 Feb;91(2):189–192. doi: 10.1111/j.1365-2249.1993.tb05880.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. O'Riordan J. I., Losseff N. A., Phatouros C., Thompson A. J., Moseley I. F., MacManus D. G., McDonald W. I., Miller D. H. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):353–357. doi: 10.1136/jnnp.64.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Offner H., Hashim G. A., Vandenbark A. A. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science. 1991 Jan 25;251(4992):430–432. doi: 10.1126/science.1989076. [DOI] [PubMed] [Google Scholar]
  28. Oksenberg J. R., Panzara M. A., Begovich A. B., Mitchell D., Erlich H. A., Murray R. S., Shimonkevitz R., Sherritt M., Rothbard J., Bernard C. C. Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature. 1993 Mar 4;362(6415):68–70. doi: 10.1038/362068a0. [DOI] [PubMed] [Google Scholar]
  29. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  30. Richert J. R., Robinson E. D., Camphausen K., Martin R., Voskuhl R. R., Faerber M. A., McFarland H. F., Hurley C. K. Diversity of T-cell receptor V alpha, V beta, and CDR3 expression by myelin basic protein-specific human T-cell clones. Neurology. 1995 Oct;45(10):1919–1922. doi: 10.1212/wnl.45.10.1919. [DOI] [PubMed] [Google Scholar]
  31. Sandberg-Wollheim M., Bynke H., Cronqvist S., Holtås S., Platz P., Ryder L. P. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol. 1990 Apr;27(4):386–393. doi: 10.1002/ana.410270406. [DOI] [PubMed] [Google Scholar]
  32. Satyanarayana K., Chou Y. K., Bourdette D., Whitham R., Hashim G. A., Offner H., Vandenbark A. A. Epitope specificity and V gene expression of cerebrospinal fluid T cells specific for intact versus cryptic epitopes of myelin basic protein. J Neuroimmunol. 1993 Apr;44(1):57–67. doi: 10.1016/0165-5728(93)90268-4. [DOI] [PubMed] [Google Scholar]
  33. Usuku K., Joshi N., Hatem C. J., Jr, Wong M. A., Stein M. C., Hauser S. L. Biased expression of T cell receptor genes characterizes activated T cells in multiple sclerosis cerebrospinal fluid. J Neurosci Res. 1996 Sep 15;45(6):829–837. doi: 10.1002/(SICI)1097-4547(19960915)45:6<829::AID-JNR20>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  34. Vandenbark A. A., Chou Y. K., Whitham R., Mass M., Buenafe A., Liefeld D., Kavanagh D., Cooper S., Hashim G. A., Offner H. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med. 1996 Oct;2(10):1109–1115. doi: 10.1038/nm1096-1109. [DOI] [PubMed] [Google Scholar]
  35. Wilson D. B., Golding A. B., Smith R. A., Dafashy T., Nelson J., Smith L., Carlo D. J., Brostoff S. W., Gold D. P. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J Neuroimmunol. 1997 Jun;76(1-2):15–28. doi: 10.1016/s0165-5728(97)00028-3. [DOI] [PubMed] [Google Scholar]
  36. Wucherpfennig K. W., Newcombe J., Li H., Keddy C., Cuzner M. L., Hafler D. A. T cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions. J Exp Med. 1992 Apr 1;175(4):993–1002. doi: 10.1084/jem.175.4.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wucherpfennig K. W., Ota K., Endo N., Seidman J. G., Rosenzweig A., Weiner H. L., Hafler D. A. Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science. 1990 May 25;248(4958):1016–1019. doi: 10.1126/science.1693015. [DOI] [PubMed] [Google Scholar]
  38. Zamvil S. S., Mitchell D. J., Moore A. C., Kitamura K., Steinman L., Rothbard J. B. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature. 1986 Nov 20;324(6094):258–260. doi: 10.1038/324258a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES